Introduction
============

Chronic thromboembolic pulmonary hypertension (CTEPH) is a serious complication of pulmonary embolism, occurring in 0.1% to 4% of patients surviving an episode of acute pulmonary embolism.^[@b1]--[@b2]^ Currently, pulmonary endarterectomy (PEA) is the only potentially curative treatment option resulting in improved functional status, hemodynamics, and overall survival.^[@b3]--[@b4]^ Despite normalization of resting mean pulmonary artery pressures (mPAP) and pulmonary vascular resistance (PVR) after PEA,^[@b5]--[@b6]^ abnormal increases in right ventricular (RV) afterload may be apparent during exercise and may explain the reduced exercise capacity that persists in many patients.^[@b7]^

Although RV afterload is often described as PVR, a more complete description is provided by incorporating measures of both resistive and pulsatile load. Pulmonary arterial compliance (C~PA~) represents the distensibility of the pulmonary circulation, whereas PVR is the ratio of mean pressure to mean flow. It has been suggested that a reduction in C~PA~ during exercise is the strongest predictor of exercise limitation in post‐PEA patients and indicative of an abnormal pulmonary vascular response to exercise.^[@b7]^ However, the consequence of an increase in RV afterload during exercise on RV contractile reserve has not been quantified in post‐PEA patients, despite RV function being the main predictor of outcome and exercise capacity in PH, irrespective of any change in PVR.^[@b8]^ Recently, we validated a novel cardiac magnetic resonance (CMR) imaging technique that enables accurate and reproducible quantification of biventricular volumes during uninterrupted strenuous exercise and continued breathing.^[@b9]^ This represents the ideal tool to investigate subtle RV dysfunction that may only become evident under the hemodynamic stress of exercise.^[@b10]^

The aim of this study was to evaluate RV afterload and RV function during exercise in patients with normalized resting mPAP after PEA. We compared post‐PEA patients with healthy controls and CTEPH patients with the hypothesis that differences in pulmonary vascular and RV function would be more appreciable during exercise and may be associated with exercise intolerance in post‐PEA patients. Furthermore, we sought to assess whether the relationship between PVR and C~PA~ remains constant during exercise in the different study populations and whether C~PA~ is a better predictor of exercise capacity than PVR or right ventricular ejection fraction (RVEF). Finally, we evaluated the effects of a single oral dose of the pulmonary vasodilator sildenafil on exercise hemodynamics and RV function in the post‐PEA patients.

Methods
=======

Subjects
--------

Fourteen healthy subjects volunteered to participate after responding to local advertisements. All subjects were (1) healthy; (2) had no history of cardiovascular disease, symptoms, or risk factors; and (3) had a normal ECG and transthoracic echocardiogram. Given the constraints of recruiting healthy subjects for an invasive study protocol, we did not attempt to match age and gender in control subjects with the CTEPH and post‐PEA patients. However, where appropriate, we included an analysis of the 7 oldest controls and 7 youngest CTEPH patients such that age and gender in the 3 comparison groups were similar.

The CTEPH group consisted of 15 consecutive patients with documented CTEPH who were referred to our institution for further investigation regarding suitability for PEA. Diagnosis of CTEPH was established in all patients by ventilation/perfusion scan, pulmonary angiography, and right heart catheterization in accordance with contemporary guidelines.^[@b11]^ None of the patients were on medical therapy with a pulmonary vasodilator.

The group of post‐PEA patients consisted of 7 patients in whom mPAP normalized (≤25 mm Hg) measured at least 6 months after PEA. Six of the post‐PEA patients were also included in the CTEPH group prior to surgery. Patients with resting mPAP \>25 mm Hg or pulmonary capillary wedge pressure (PCWP) \>15 mm Hg after surgery were excluded.

The study protocol conformed to the Declaration of Helsinki and was approved by the local ethics committee. All patients provided informed consent.

Study Design
------------

First, cardiopulmonary exercise testing was performed on an upright cycle ergometer (ER900 and Oxycon Alpha, Jaeger, Germany) using a continuous ramp protocol until exhaustion. Breath‐by‐breath analysis provided measures of oxygen consumption at peak exercise (VO~2~ peak), maximal power output in watts (P~max~), and the minute ventilation--carbon dioxide production relationship (VE/VCO~2~ slope)**.**

Twenty‐four hours later, all subjects underwent exercise CMR with simultaneous invasive pressure measurement. Prior to exercise, a 7‐Fr pulmonary artery catheter was inserted in the internal jugular vein and guided under fluoroscopy or pressure curve monitoring to the proximal right main pulmonary artery. A 20‐gauge arterial catheter was placed in the radial artery. In the CMR suite, these catheters were attached to CMR‐compatible pressure transducers that were connected to a PowerLab recording system (AD Instruments, Oxford, United Kingdom).

Patients underwent exercise CMR at rest and at 25%, 50%, and 66% of maximal power output in watts determined during the previous cardiopulmonary exercise testing. We have previously demonstrated that 66% of the maximal upright exercise power (in watts) corresponded to the maximal sustainable exercise intensity in a supine position.^[@b9]^ Thus, these workloads will subsequently be referred to as rest, low‐, moderate‐, and peak‐intensity exercise. During the exercise CMR protocol, pulmonary and systemic arterial pressures were continuously recorded by the pulmonary and radial artery catheters and analyzed off‐line using LabChart v6.1.1 (AD Instruments). All pressure measurements were averaged over 10 consecutive cardiac cycles during unrestricted respiration.^[@b12]^ In the post‐PEA patients, exercise CMR was repeated 30 to 60 minutes after administration of a single oral dose of sildenafil. The same absolute workload was used during both the baseline and postsildenafil exercise evaluation.

CMR Equipment, Image Acquisition, and Analysis
----------------------------------------------

Biventricular volumes were measured during supine cycling exercise using a real‐time CMR method that we previously described in detail and have validated against invasive standards.^[@b9]^ In brief, subjects performed supine exercise within the CMR bore using a cycle ergometer with adjustable electronic resistance (Lode, Groningen, The Netherlands). Images were acquired with a Philips Achieva 1.5 T CMR with a 5‐element phased‐array coil (Philips Medical Systems, Best, The Netherlands).

Using an in‐house‐developed software program (RightVol, Leuven, Belgium), LV and RV endocardial contours were manually traced on a stack of short‐axis image slices with simultaneous reference to the horizontal long‐axis plane, thus enabling the analyzers (G.C. and A.L.G.) to confirm the position of the atrioventricular plane. End‐diastolic and end‐systolic volumes (EDV and ESV) were calculated by a summation of disks. Stroke volume (SV) was measured as the difference between EDV and ESV. Cardiac output (CO) was measured as the product of SV and heart rate, while ejection fraction (EF) was calculated as SV/EDV. Total pulmonary resistance (tPVR) was defined as the ratio of mPAP to CO and total systemic vascular resistance as the ratio of mean systemic arterial pressure to CO. C~PA~ was calculated as the ratio of RVSV to pulmonary arterial pulse pressure. The time constant of the pulmonary circulation (RC time) was calculated as the product of tPVR (in mm Hg·s·mL^−1^) and C~PA~.

Statistics
----------

Data were analyzed using IBM SPSS statistics 22 software. Descriptive data for continuous variables are presented as means±SD or as medians (25% and 75% percentile) when appropriate. Comparisons between groups were performed using 1way ANOVA and Bonferroni post‐hoc test for multiple comparisons. The effects of sildenafil in the post‐PEA group were assessed using a paired‐samples *t* test. The biventricular volume response from rest to peak‐intensity exercise was evaluated using a repeated‐measures ANOVA with exercise intensity as within‐subject effect and group (post‐PEA patients versus controls versus CTEPH) as a between‐subject effect. Individual mPAP‐flow slope coefficients were derived from serial measurements of mPAP and CO during incremental exercise using linear regression analysis.^[@b12]^ Differences in mPAP/CO slope coefficients between groups were compared using 1‐way ANOVA.

Pearson correlation coefficients were used to assess the univariate relationships between C~PA~ and VO~2~ peak. To demonstrate the relationship between tPVR and C~PA~, a nonlinear curve was fitted according to the formula y=cte/x (hyperbola formula). The impact of exercise on the tPVR--C~PA~ relation was evaluated by a linear mixed model that included tPVR, condition (rest versus exercise), and their interaction as fixed effects. To account for the repeated nature of the data, an unstructured variance--covariance matrix was included in the model. Both C~PA~ and tPVR were log‐transformed to obtain a linear association between the 2. To increase the certainty of correct assumptions given the number of tests performed in our experiments, a *P*‐value \<0.01 was considered significant.

Results
=======

Clinical Characteristics
------------------------

The clinical characteristics and cardiopulmonary exercise testing data are depicted in [Table 1](#tbl01){ref-type="table"}. CTEPH and post‐PEA patients were older than the controls, whereas gender proportions were similar. Some of the CTEPH and post‐PEA patients were receiving negative chronotropic medications that were withheld for 24 hours prior to testing. Nevertheless, peak heart rate was significantly lower in post‐PEA and CTEPH patients compared to controls. Post‐PEA patients were in lower New York Heart Association functional class than CTEPH patients, although their VO~2~ peak was similar.

###### 

Clinical Characteristics

                                  Healthy Controls (n=14)   CTEPH (n=15)                                       Post‐PEA (n=7)                              *P* Value
  ------------------------------- ------------------------- -------------------------------------------------- ------------------------------------------- -----------
  Clinical                                                                                                                                                 
  Age, y                          36±15                     62±13[\*](#tf1-1){ref-type="table-fn"}             62±12[\*](#tf1-1){ref-type="table-fn"}      \<0.0001
  BSA, m^2^                       1.88±0.21                 1.94±0.28                                          1.99±0.14                                   0.553
  BMI, kg/m^2^                    24.2±5.2                  28.2±5.4                                           29.8±5.6                                    0.048
  Sex, M (F)                      11 (3)                    10 (5)                                             6 (1)                                       0.583
  NYHA class                                                                                                                                               
  I                               --                        1                                                  3                                           0.040
  II                              --                        4                                                  3                                           0.448
  III                             --                        10                                                 1                                           0.022
  IV                              --                        0                                                  0                                           
  Medications                                                                                                                                              
  Pulmonary vasodilators          0                         0                                                  0                                           
  Negative chronotropic drugs                               5                                                  4                                           0.290
  β‐Blockers                      --                        4                                                  2                                           0.926
  Amiodarone                      --                        1                                                  2                                           0.163
  Digoxin                         --                        1                                                  1                                           0.563
  Biochemical                                                                                                                                              
  NTproBNP, ng/L                  28 (5--41)                399 (232--1271)[\*](#tf1-1){ref-type="table-fn"}   118 (66--343)                               \<0.0001
  CPET                                                                                                                                                     
  VO~2~ peak, mL·kg^−1^·min^−1^   34.4±8.0                  13.0±3.3[\*](#tf1-1){ref-type="table-fn"}          15.0±4.3[\*](#tf1-1){ref-type="table-fn"}   \<0.0001
  VO~2~ peak, % of predicted      94±24                     55±17[\*](#tf1-1){ref-type="table-fn"}             63±15[\*](#tf1-1){ref-type="table-fn"}      \<0.0001
  Peak HR, bpm                    174±18                    126±19[\*](#tf1-1){ref-type="table-fn"}            114±23[\*](#tf1-1){ref-type="table-fn"}     \<0.0001
  Peak power, W                   215±67                    77±29[\*](#tf1-1){ref-type="table-fn"}             91±37[\*](#tf1-1){ref-type="table-fn"}      \<0.0001
  VE/VCO~2~                       0.026±0.005               0.043±0.006[\*](#tf1-1){ref-type="table-fn"}       0.035±0.005                                 \<0.0001

BMI indicates body mass index; BSA, body surface area; CPET, cardiopulmonary exercise testing; CTEPH, chronic thromboembolic pulmonary hypertension; F, female; HR, heart rate; M, male; NTproBNP, N‐terminal pro‐brain natriuretic peptide; NYHA, New York Heart Association; post‐PEA, patients after pulmonary endarterectomy; VE/VCO~2~, minute ventilation‐carbon dioxide production relationship; VO~2~, oxygen consumption; W, watts.

*P*\<0.01 vs healthy controls.

Data presented as mean±SD or median (25% and 75% percentile).

Central Hemodynamics and Biventricular Function
-----------------------------------------------

As demonstrated in [Table 2](#tbl02){ref-type="table"}, resting tPVR was lower in post‐PEA patients than in CTEPH patients (*P*\<0.0001) and tended to be higher than in controls (*P*=0.059). Resting C~PA~ was higher in controls than in post‐PEA and CTEPH patients (*P*\<0.0001) and correlated strongly with VO~2~ peak ([Figure 1](#fig01){ref-type="fig"}A). Resting RVESV was larger, and RVEF lower in CTEPH patients relative to both controls and post‐PEA patients (*P*\<0.0001), the latter 2 groups having similar values. LVEDV and LVESV were smaller in CTEPH and post‐PEA patients than in controls, whereas LVEF was similar in all groups.

###### 

Biventricular Function and Hemodynamics During Exercise CMR With Simultaneous Invasive Pressure Measurement

                             Controls (n=14)   CTEPH (n=15)                                 Post‐PEA (n=7)                                                               *P* Value
  -------------------------- ----------------- -------------------------------------------- ---------------------------------------------------------------------------- -----------
  HR, bpm                                                                                                                                                                
  Rest                       66±7              78±12                                        82±14                                                                        0.004
  Peak ex                    149±11            120±20[\*](#tf2-1){ref-type="table-fn"}      108±26[\*](#tf2-1){ref-type="table-fn"}                                      \<0.0001
  mPAP, mm Hg                                                                                                                                                            
  Rest                       10±3              44±10[\*](#tf2-1){ref-type="table-fn"}       21±5[\*](#tf2-1){ref-type="table-fn"}[\*](#tf2-2){ref-type="table-fn"}       \<0.0001
  Peak ex                    22±8              65±11[\*](#tf2-1){ref-type="table-fn"}       38±4[\*](#tf2-1){ref-type="table-fn"}[\*](#tf2-2){ref-type="table-fn"}       \<0.0001
  PA pulse pressure, mm Hg                                                                                                                                               
  Rest                       10±3              52±11[\*](#tf2-1){ref-type="table-fn"}       25±6[\*](#tf2-1){ref-type="table-fn"}[\*](#tf2-2){ref-type="table-fn"}       \<0.0001
  Peak ex                    24±11             78±16[\*](#tf2-1){ref-type="table-fn"}       48±10[\*](#tf2-1){ref-type="table-fn"}[\*](#tf2-2){ref-type="table-fn"}      \<0.0001
  PCWP, mm Hg                                                                                                                                                            
  Rest                       --                10±3                                         9±2                                                                          0.902
  Peak ex                    --                --                                           --                                                                           --
  mSAP, mm Hg                                                                                                                                                            
  Rest                       93±14             93±13                                        84±17                                                                        0.351
  Peak ex                    114±15            115±22                                       97±13                                                                        0.302
  LVEDV, mL                                                                                                                                                              
  Rest                       162±44            112±27[\*](#tf2-1){ref-type="table-fn"}      117±18                                                                       0.001
  Peak ex                    156±43            102±26[\*](#tf2-1){ref-type="table-fn"}      129±20                                                                       0.001
  RVEDV, mL                                                                                                                                                              
  Rest                       161±47            177±46                                       128±18                                                                       0.059
  Peak ex                    148±43            200±43[\*](#tf2-1){ref-type="table-fn"}      157±26                                                                       0.005
  LVESV, mL                                                                                                                                                              
  Rest                       68±24             44±16[\*](#tf2-1){ref-type="table-fn"}       42±13                                                                        0.003
  Peak ex                    48±14             36±15                                        46±11                                                                        0.083
  RVESV, mL                                                                                                                                                              
  Rest                       69±26             114±37[\*](#tf2-1){ref-type="table-fn"}      56±12[\*](#tf2-2){ref-type="table-fn"}                                       \<0.0001
  Peak ex                    42±15             132±35[\*](#tf2-1){ref-type="table-fn"}      70±15[\*](#tf2-2){ref-type="table-fn"}                                       \<0.0001
  LVSV, mL                                                                                                                                                               
  Rest                       94±24             68±17[\*](#tf2-1){ref-type="table-fn"}       75±8                                                                         0.002
  Peak ex                    108±32            66±21[\*](#tf2-1){ref-type="table-fn"}       83±12                                                                        \<0.0001
  RVSV, mL                                                                                                                                                               
  Rest                       92±24             63±15[\*](#tf2-1){ref-type="table-fn"}       73±8                                                                         \<0.0001
  Peak ex                    107±30            68±20[\*](#tf2-1){ref-type="table-fn"}       87±14                                                                        0.001
  LVEF, %                                                                                                                                                                
  Rest                       58.8±5.7          61.3±9.1                                     64.5±6.2                                                                     0.258
  Peak ex                    69.2±4.4          64.5±12.5                                    64.8±4.6                                                                     0.316
  RVEF, %                                                                                                                                                                
  Rest                       58.3±5.5          36.2±6.4[\*](#tf2-1){ref-type="table-fn"}    57.0±4.5[\*](#tf2-2){ref-type="table-fn"}                                    \<0.0001
  Peak ex                    72.2±5.0          34.0±8.2[\*](#tf2-1){ref-type="table-fn"}    55.9±4.2[\*](#tf2-1){ref-type="table-fn"}[\*](#tf2-2){ref-type="table-fn"}   \<0.0001
  CO, L/min                                                                                                                                                              
  Rest                       6.2±1.9           5.1±1.6                                      6.1±1.4                                                                      0.200
  Peak ex                    16.2±5.3          7.9±0.7[\*](#tf2-1){ref-type="table-fn"}     9.5±3.8[\*](#tf2-1){ref-type="table-fn"}                                     \<0.0001
  CI, L/min per m^2^                                                                                                                                                     
  Rest                       3.3±0.8           2.6±0.6                                      3.1±0.7                                                                      0.059
  Peak ex                    8.5±2.3           4.0±1.0[\*](#tf2-1){ref-type="table-fn"}     4.7±1.7[\*](#tf2-1){ref-type="table-fn"}                                     \<0.0001
  PVR, dynes·s·cm^−5^                                                                                                                                                    
  Rest                       --                584±182                                      160±67[\*](#tf2-2){ref-type="table-fn"}                                      \<0.0001
  Peak ex                    --                --                                           --                                                                           --
  tPVR, dynes·s·cm^−5^                                                                                                                                                   
  Rest                       134±49            728±191[\*](#tf2-1){ref-type="table-fn"}     287±105[\*](#tf2-2){ref-type="table-fn"}                                     \<0.0001
  Peak ex                    114±49            724±258[\*](#tf2-1){ref-type="table-fn"}     364±124[\*](#tf2-2){ref-type="table-fn"}                                     \<0.0001
  tPVR, wood units                                                                                                                                                       
  Rest                       1.7±0.6           9.1±2.4[\*](#tf2-1){ref-type="table-fn"}     3.6±1.2[\*](#tf2-2){ref-type="table-fn"}                                     \<0.0001
  Peak ex                    1.4±0.6           9.1±3.2[\*](#tf2-1){ref-type="table-fn"}     4.6±1.6[\*](#tf2-2){ref-type="table-fn"}                                     \<0.0001
  tSVR, dynes·s·cm^−5^                                                                                                                                                   
  Rest                       1310±477          1580±558                                     1160±374                                                                     0.148
  Peak ex                    617±200           1274±472[\*](#tf2-1){ref-type="table-fn"}    922±409                                                                      0.001
  C~PA~, mL/mm Hg                                                                                                                                                        
  Rest                       9.7±3.1           1.3±0.4[\*](#tf2-1){ref-type="table-fn"}     3.1±0.6[\*](#tf2-1){ref-type="table-fn"}                                     \<0.0001
  Peak ex                    5.1±1.8           0.9±0.3[\*](#tf2-1){ref-type="table-fn"}     1.9±0.3[\*](#tf2-1){ref-type="table-fn"}                                     \<0.0001
  RC time, s                                                                                                                                                             
  Rest                       0.89±0.25         0.65±0.11[\*](#tf2-1){ref-type="table-fn"}   0.64±0.22                                                                    0.002
  Peak ex                    0.41±0.17         0.44±0.10                                    0.51±0.22                                                                    0.358

CI indicates cardiac index; CMR, cardiac magnetic resonance; CO, cardiac output; C~PA~, pulmonary arterial compliance; CTEPH, chronic thromboembolic pulmonary hypertension; EDV, end‐diastolic volume; EF, ejection fraction; ESV, end‐systolic volume; ex, exercise; HR, heart rate; LV, left ventricle; mPAP, mean pulmonary arterial pressure; mSAP, mean systemic arterial pressure; PA, pulmonary arterial; PCWP, pulmonary capillary wedge pressure; post‐PEA, patients after pulmonary endarterectomy; PVR, pulmonary vascular resistance; RC, time constant; RV, right ventricle; SV, stroke volume; tPVR, total pulmonary vascular resistance; tSVR, total systemic vascular resistance.

*P*\<0.01 vs healthy controls.

*P*\<0.01 vs CTEPH.

![Correlation between (A) peak oxygen consumption (VO~2~ peak) and pulmonary arterial compliance (C~PA~) at rest and (B) between VO~2~ peak and the change in C~PA~ from rest to peak exercise (∆C~PA~).](jah3-4-e001602-g1){#fig01}

As illustrated in [Figure 2](#fig02){ref-type="fig"}A, the slope of mPAP/CO plots was steeper in post‐PEA patients relative to controls, but similar to CTEPH patients (4.7 \[4.2--10.3\] versus 1.0 \[0.8--1.7\] versus 6.7 \[5.2--10.1\] mm Hg/L per minute, respectively; *P*\<0.0001). From rest to peak exercise, tPVR did not change significantly in healthy controls (*P*=0.064) and CTEPH patients (*P*=0.960), whereas it tended to increase in post‐PEA patients (*P*=0.018; [Figure 2](#fig02){ref-type="fig"}B). In contrast, C~PA~ decreased in all subjects during exercise. The absolute exercise‐induced reduction in C~PA~ correlated highly with VO~2~ peak ([Figure 1](#fig01){ref-type="fig"}B). Overall, the exercise reduction in C~PA~ was greatest in controls ([Figure 4](#fig04){ref-type="fig"}A). However, peak exercise C~PA~ in control subjects still remained higher than the resting values in CTEPH and post‐PEA patients (*P*\<0.01). These significant differences in C~PA~ and mPAP/CO slope were preserved when the oldest control subjects were considered for an age‐matched comparison ([Table 3](#tbl03){ref-type="table"}).

###### 

Comparison of Biventricular Function and Hemodynamics Between Age‐Matched Controls, CTEPH, and Post‐PEA Patients

                             Controls (n=7)   CTEPH (n=7)                                 Post‐PEA (n=7)                                                               *P* Value
  -------------------------- ---------------- ------------------------------------------- ---------------------------------------------------------------------------- -----------
  Age, y                     48±11            58±16                                       62±12                                                                        0.14
  HR, bpm                                                                                                                                                              
  Rest                       64±6             80±17                                       82±14                                                                        0.030
  Peak ex                    148±12           112±23                                      108±26[\*](#tf3-1){ref-type="table-fn"}                                      0.004
  mPAP, mm Hg                                                                                                                                                          
  Rest                       11±3             45±11[\*](#tf3-1){ref-type="table-fn"}      21±5[\*](#tf3-2){ref-type="table-fn"}                                        \<0.0001
  Peak ex                    25±8             61±13[\*](#tf3-1){ref-type="table-fn"}      38±4[\*](#tf3-2){ref-type="table-fn"}                                        \<0.0001
  PA pulse pressure, mm Hg                                                                                                                                             
  Rest                       12±3             52±12[\*](#tf3-1){ref-type="table-fn"}      25±6[\*](#tf3-2){ref-type="table-fn"}                                        \<0.0001
  Peak ex                    30±10            76±16[\*](#tf3-1){ref-type="table-fn"}      48±10[\*](#tf3-2){ref-type="table-fn"}                                       \<0.0001
  mSAP, mm Hg                                                                                                                                                          
  Rest                       103±12           90±15                                       84±17                                                                        0.068
  Peak ex                    123±11           108±20                                      97±13                                                                        0.265
  LVEDV, mL                                                                                                                                                            
  Rest                       162±41           120±30                                      117±18                                                                       0.024
  Peak ex                    153±37           111±28                                      129±20                                                                       0.046
  RVEDV, mL                                                                                                                                                            
  Rest                       160±47           192±48                                      128±18                                                                       0.027
  Peak ex                    145±36           211±42[\*](#tf3-1){ref-type="table-fn"}     157±26                                                                       0.006
  LVESV, mL                                                                                                                                                            
  Rest                       64±20            47±17                                       42±13                                                                        0.056
  Peak ex                    44±12            37±14                                       46±11                                                                        0.429
  RVESV, mL                                                                                                                                                            
  Rest                       65±23            124±45[\*](#tf3-1){ref-type="table-fn"}     56±12[\*](#tf3-2){ref-type="table-fn"}                                       0.001
  Peak ex                    37±13            138±43[\*](#tf3-1){ref-type="table-fn"}     70±15[\*](#tf3-2){ref-type="table-fn"}                                       \<0.0001
  LVSV, mL                                                                                                                                                             
  Rest                       98±25            74±14                                       75±8                                                                         0.026
  Peak ex                    110±27           74±18                                       83±12                                                                        0.010
  RVSV, mL                                                                                                                                                             
  Rest                       94±26            68±12                                       73±8                                                                         0.020
  Peak ex                    108±26           73±16                                       87±14                                                                        0.011
  LVEF, %                                                                                                                                                              
  Rest                       60.8±5.7         62.0±5.5                                    64.5±6.2                                                                     0.487
  Peak ex                    71.6±3.5         67.1±6.5                                    64.8±4.6                                                                     0.060
  RVEF, %                                                                                                                                                              
  Rest                       59.7±6.2         36.6±8.2[\*](#tf3-1){ref-type="table-fn"}   57.0±4.5[\*](#tf3-2){ref-type="table-fn"}                                    \<0.0001
  Peak ex                    75.0±4.8         35.7±9.8[\*](#tf3-1){ref-type="table-fn"}   55.9±4.2[\*](#tf3-1){ref-type="table-fn"}[\*](#tf3-2){ref-type="table-fn"}   \<0.0001
  CO, L/min                                                                                                                                                            
  Rest                       6.2±1.8          5.7±1.7                                     6.1±1.4                                                                      0.840
  Peak ex                    16.4±5.0         8.3±2.7[\*](#tf3-1){ref-type="table-fn"}    9.5±3.8                                                                      0.002
  CI, L/min per m^2^                                                                                                                                                   
  Rest                       3.2±0.8          2.8±0.8                                     3.1±0.7                                                                      0.624
  Peak ex                    8.5±2.4          4.1±1.3[\*](#tf3-1){ref-type="table-fn"}    4.7±1.7[\*](#tf3-1){ref-type="table-fn"}                                     0.001
  tPVR, dynes·s·cm^−5^                                                                                                                                                 
  Rest                       157±57           669±230[\*](#tf3-1){ref-type="table-fn"}    287±105[\*](#tf3-2){ref-type="table-fn"}                                     \<0.0001
  Peak ex                    127±57           651±289[\*](#tf3-1){ref-type="table-fn"}    364±124[\*](#tf3-2){ref-type="table-fn"}                                     \<0.0001
  tPVR, wood units                                                                                                                                                     
  Rest                       2.0±0.7          8.4±2.9[\*](#tf3-1){ref-type="table-fn"}    3.6±1.2[\*](#tf3-2){ref-type="table-fn"}                                     \<0.0001
  Peak ex                    1.6±0.7          8.1±3.6[\*](#tf3-1){ref-type="table-fn"}    4.6±1.6[\*](#tf3-2){ref-type="table-fn"}                                     \<0.0001
  tSVR, dynes·s·cm^−5^                                                                                                                                                 
  Rest                       1475±572         1327±284                                    1160±374                                                                     0.405
  Peak ex                    660±228          1109±283                                    922±409                                                                      0.102
  C~PA~, mL/mm Hg                                                                                                                                                      
  Rest                       8.5±3.6          1.4±0.4[\*](#tf3-1){ref-type="table-fn"}    3.1±0.6[\*](#tf3-1){ref-type="table-fn"}                                     \<0.0001
  Peak ex                    3.9±0.9          1.0±0.3[\*](#tf3-1){ref-type="table-fn"}    1.9±0.3[\*](#tf3-1){ref-type="table-fn"}                                     \<0.0001
  RC time, s                                                                                                                                                           
  Rest                       0.88±0.18        0.64±0.14                                   0.64±0.22                                                                    0.031
  Peak ex                    0.37±0.20        0.45±0.12                                   0.51±0.22                                                                    0.358

CI indicates cardiac index; CO, cardiac output; C~PA~, pulmonary arterial compliance; CTEPH, chronic thromboembolic pulmonary hypertension; EDV, end‐diastolic volume; EF, ejection fraction; ESV, end‐systolic volume; ex, exercise; HR, heart rate; LV, left ventricle; mPAP, mean pulmonary arterial pressure; mSAP, mean systemic arterial pressure; PA, pulmonary arterial; post‐PEA, patients after pulmonary endarterectomy; RC, time constant; RV, right ventricle; SV, stroke volume; tPVR, total pulmonary vascular resistance; tSVR, total systemic vascular resistance.

*P*\<0.01 vs healthy controls.

*P*\<0.01 vs CTEPH.

![Pulmonary vascular and right ventricular reserve in healthy subjects, patients with chronic thromboembolic pulmonary hypertension (CTEPH), and patients after pulmonary endarterectomy (post‐PEA). A, Relationship between mean pulmonary artery pressure (mPAP) and cardiac output during incremental exercise. Changes in (B) total pulmonary vascular resistance (tPVR), (C) right ventricular end‐systolic volume (RVESV), and (D) RV ejection fraction (RVEF) from rest to peak exercise. At each exercise intensity, \**P*\<0.01 for difference between healthy controls and CTEPH patients, ^†^*P*\<0.01 for difference between healthy controls and post‐PEA patients, and ^‡^*P*\<0.01 for difference between CTEPH and post‐PEA patients.](jah3-4-e001602-g2){#fig02}

From rest to peak exercise, RVESV decreased in controls and increased in CTEPH and post‐PEA patients (*P*\<0.0001 for interaction between within‐subject changes during exercise versus between‐subject groups; [Figure 2](#fig02){ref-type="fig"}C). Similarly, RVEDV decreased in controls, whereas it increased in CTEPH and post‐PEA patients (*P*\<0.0001 for interaction). Therefore, contrary to resting measures, peak exercise RVEF was reduced both in CTEPH and in post‐PEA patients relative to controls (both *P*\<0.0001; [Figure 2](#fig02){ref-type="fig"}D). The changes in RVEF at rest and at near‐maximal intensity exercise for all individual subjects are plotted in [Figure 3](#fig03){ref-type="fig"}. Between the patient groups, post‐PEA patients had higher RVEF and smaller RVESV throughout exercise, respectively, than CTEPH patients ([Table 2](#tbl02){ref-type="table"}).

![Individual changes in right ventricular end‐systolic volume (RVESV) and ejection fraction (RVEF) from rest to peak exercise. A, RVESV decreases from rest to peak exercise in all healthy subjects (green lines and symbols), whereas an increase is seen in post‐PEA patients (blue lines) and CTEPH patients (red lines). B, All healthy subjects demonstrate an increase in RVEF during exercise as opposed to CTEPH and post‐PEA patients. CTEPH indicates chronic thromboembolic pulmonary hypertension; post‐PEA, patients after pulmonary endarterectomy.](jah3-4-e001602-g3){#fig03}

At rest, the RC time (product of tPVR and C~PA~) was lower in patients with CTEPH than in healthy controls (*P*=0.005; [Figure 4](#fig04){ref-type="fig"}B). At peak exercise, the RC time was similar between the different groups. [Figure 5](#fig05){ref-type="fig"}A depicts the inverse relationship between tPVR and C~PA,~ both at rest and peak exercise. At peak exercise, the tPVR--C~PA~ relation is shifted downward and to the left. [Figure 5](#fig05){ref-type="fig"}B shows a plot of log(tPVR) against log(C~PA~) for all groups. The lines show the best fits for rest (green line) and peak exercise (red line). Linear mixed‐model analysis showed a significant difference in the slopes of the lines (*P*=0.002). Thus, for each given value of tPVR, C~PA~ was lower during peak exercise than at rest and the difference was most profound in those subjects with the lowest tPVR and highest C~PA~ at rest (ie, healthy subjects).

![Effect of exercise on pulmonary arterial compliance (C~PA~). A, C~PA~ decreases in all groups with increasing cardiac output. Although C~PA~ decreases during exercise even in healthy subjects, C~PA~ is significantly lower at rest and throughout exercise in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and patients after pulmonary endarterectomy (post‐PEA). B, Mean resistance‐compliance product (RC time) for each subgroup relative to cardiac output. The RC time is lower at rest in CTEPH patients and post‐PEA patients relative to healthy subjects and decreases in all groups during exercise. At each exercise intensity, \**P*\<0.01 for difference between healthy controls and CTEPH and ^†^*P*\<0.01 for difference between healthy controls and post‐PEA patients.](jah3-4-e001602-g4){#fig04}

![Effect of exercise on the pulmonary vascular resistance‐compliance relationship (tPVR--C~PA~). A, tPVR--C~PA~ for each subject is plotted at rest and at peak exercise (66% of maximal power during cardiopulmonary exercise testing). B, Plot of log(tPVR) against log(C~PA~) for healthy subjects, patients with chronic thromboembolic pulmonary hypertension (CTEPH), and patients after pulmonary endarterectomy (post‐PEA). Best‐fit lines are shown for rest (green line, *R*^2^=0.91) and peak exercise (red line, *R*^2^=0.85). Linear mixed‐model analysis showed a significant difference in the slopes of the lines as depicted by the arrow (\**P*=0.002).](jah3-4-e001602-g5){#fig05}

Acute Effect of Sildenafil on Exercise Hemodynamics and RV Function in Post‐PEA Patients
----------------------------------------------------------------------------------------

The administration of sildenafil did not affect hemodynamics or RV function in the post‐PEA patients when measured at rest ([Table 4](#tbl04){ref-type="table"}). In contrast, exercise measures improved significantly following sildenafil. Sildenafil decreased the mPAP/CO slope and peak exercise tPVR ([Figure 6](#fig06){ref-type="fig"}), whereas peak exercise C~PA~ increased (*P*=0.010). This was associated with a reduction in RVESV and an increase in RVEF at peak exercise (*P*\<0.01), whereas peak exercise LVESV and LVEF were unchanged. The RC time remained constant before and after sildenafil ([Figure 7](#fig07){ref-type="fig"}).

###### 

Comparison of Biventricular Function and Hemodynamics Before and After Sildenafil in Post‐PEA Patients

                             Post‐PEA (n=7)   *P* Value   
  -------------------------- ---------------- ----------- ----------
  HR, bpm                                                 
  Rest                       82±14            86±9        0.759
  Peak ex                    108±26           112±23      0.929
  mPAP, mm Hg                                             
  Rest                       21±5             18±4        0.117
  Peak ex                    38±4             30±2        \<0.0001
  PA pulse pressure, mm Hg                                
  Rest                       25±6             21±5        0.035
  Peak ex                    48±10            42±10       \<0.0001
  mSAP, mm Hg                                             
  Rest                       84±17            86±8        0.383
  Peak ex                    97±13            105±9       0.010
  LVEDV, mL                                               
  Rest                       117±18           113±17      0.671
  Peak ex                    129±20           130±22      0.804
  RVEDV, mL                                               
  Rest                       128±18           130±23      0.301
  Peak ex                    157±26           146±29      0.051
  LVESV, mL                                               
  Rest                       42±13            39±10       0.913
  Peak ex                    46±11            40±11       0.177
  RVESV, mL                                               
  Rest                       56±12            57±14       0.055
  Peak ex                    70±15            56±12       0.007
  LVSV, mL                                                
  Rest                       75±8             74±11       0.784
  Peak ex                    83±12            90±13       0.153
  RVSV, mL                                                
  Rest                       73±8             73±14       0.617
  Peak ex                    87±14            90±18       0.390
  LVEF, %                                                 
  Rest                       64.5±6.2         65.7±6.0    0.971
  Peak ex                    64.8±4.6         69.9±4.2    0.099
  RVEF, %                                                 
  Rest                       57.0±4.5         56.4±5.8    0.577
  Peak ex                    55.9±4.2         61.9±1.2    0.007
  CO, L/min                                               
  Rest                       6.1±1.4          6.4±1.6     0.500
  Peak ex                    9.5±0.9          10.3±3.5    0.391
  CI, L/min per m^2^                                      
  Rest                       3.1±0.7          3.1±0.8     0.529
  Peak ex                    4.7±1.7          5.1±1.6     0.398
  tPVR, dynes·s·cm^−5^                                    
  Rest                       287±105          247±90      0.086
  Peak ex                    364±124          252±84      0.003
  tSVR, dynes·s·cm^−5^                                    
  Rest                       1160±374         1166±383    0.270
  Peak ex                    922±409          887±295     0.024
  C~PA~, mL/mm Hg                                         
  Rest                       3.1±0.6          3.6±1.2     0.128
  Peak ex                    1.9±0.3          2.2±0.5     0.010
  RC time, s                                              
  Rest                       0.64±0.22        0.63±0.21   0.700
  Peak ex                    0.51±0.22        0.41±0.14   0.039

CI indicates cardiac index; CO, cardiac output; C~PA~, pulmonary arterial compliance; EDV, end‐diastolic volume; EF, ejection fraction; ESV, end‐systolic volume; ex, exercise; HR, heart rate; LV, left ventricle; mPAP, mean pulmonary arterial pressure; mSAP, mean systemic arterial pressure; PA, pulmonary arterial; post‐PEA, patients after pulmonary endarterectomy; RC, time constant; RV, right ventricle; SV, stroke volume; tPVR, total pulmonary vascular resistance; tSVR, total systemic vascular resistance.

![Sildenafil increases pulmonary vascular and right ventricular reserve in patients after pulmonary endarterectomy (post‐PEA). A, Relationship between mean pulmonary artery pressure (mPAP) and cardiac output (CO) before and after sildenafil. Changes in (B) total pulmonary vascular resistance (tPVR), (C) right ventricular end‐systolic volume (RVESV), and (D) RV ejection fraction (RVEF) from rest to peak exercise. Values are shown for the interaction between sildenafil administration and exercise intensity as within‐subjects effects. At each exercise intensity, \**P*\<0.01 for the difference between baseline and sildenafil.](jah3-4-e001602-g6){#fig06}

![Effect of sildenafil on pulmonary arterial compliance (C~PA~) and mean resistance--compliance product (RC time) in patients after pulmonary endarterectomy. Changes in (A) C~PA~ and (B) RC time from rest to peak exercise before and after sildenafil. At each exercise intensity, \**P*=0.01 for the difference between baseline and sildenafil.](jah3-4-e001602-g7){#fig07}

Discussion
==========

The present study documents significant exercise intolerance in post‐PEA subjects despite a decrease of mPAP to near‐normal values and normal RVEF at rest. Using novel exercise CMR combined with invasive PAP measures, this reduction in exercise capacity can be explained by (1) increased RV afterload during exercise, and (2) significant chronotropic impairment. Despite increased resistive and pulsatile RV afterload, post‐PEA patients have an increase in SV from rest to peak exercise, in contrast to CTEPH. However, SV augmentation during exercise in post‐PEA patients is associated with an increase in RV volumes as opposed to the observed reduction in healthy subjects. These hemodynamic abnormalities during exercise were partially reversible after administration of a single oral dose of sildenafil. Thus, exercise measures provide critical insights into the pathophysiological mechanisms underpinning exercise intolerance in post‐PEA patients and raise clinical questions as to whether there may be a role for pulmonary vasodilators in further improving pulmonary vascular physiology and functional capacity.

Exercise Evaluation Facilitates Recognition of Subtle Pulmonary Vascular Disease
--------------------------------------------------------------------------------

For patients with CTEPH, PEA is the "gold standard" procedure and currently the only potentially "curative" treatment option.^[@b13]^ After successful PEA, most patients have a sustained improvement of functional status, hemodynamics, RV function,^[@b3]^ and overall survival.^[@b4]^ Nevertheless, despite a normalization of mPAP and/or PVR, exercise capacity does not return to normal in a significant proportion of patients after PEA.^[@b5]--[@b6]^ This may be explained by a degree of residual thrombi in subsegmental pulmonary arteries and/or distal arteriopathy, thereby decreasing pulmonary vascular reserve although resting PVR is in the normal range. In these patients, the detection of abnormal pulmonary vascular reserve during exercise is important as it provides pathophysiological insights into the mechanisms limiting exercise capacity after PEA.^[@b7]^ It also provides measures that can be used to assess whether early surgical and pharmacological interventions may improve exercise hemodynamics, functional capacity, and prognosis.

Despite the rationale for exercise evaluation, the definition of a clear‐cut threshold for a normal pulmonary vascular response to exercise has been a source of debate, given that healthy individuals frequently exceed the proposed cut‐off value of mPAP=30 mm Hg during exercise, especially trained athletes and those aged \>50 years.^[@b14]--[@b16]^ Indeed, due to the near linear relationship between mPAP and CO, highly trained athletes can attain considerably higher mPAP at peak exercise compared to nonathletes, as they are able to achieve higher COs.^[@b15]--[@b16]^ Thus, pulmonary artery pressures should be considered relative to workload and/or CO. Currently, based on multiple invasive and noninvasive studies, it has been suggested that a mPAP/CO slope of \>3 mm Hg/L per minute represents an abnormal pulmonary vascular response to exercise.^[@b12]^ Accordingly, the pulmonary vascular response of the post‐PEA patients in our study can be considered abnormal, despite their resting mPAP and PVR being below the threshold of persistent postoperative PH.^[@b17]^

A second mechanism that contributed substantially to the impaired CO augmentation and exercise intolerance in the post‐PEA patients was an attenuated heart rate response. The observed chronotropic incompetence may have been compounded by the recent use of negative chronotropic medications in some patients but may also reflect the disease process. In patients with pulmonary arterial hypertension, chronotropic incompetence has been associated with RV myocardial β‐adrenoreceptor downregulation in proportion to the physiologic severity of disease.^[@b18]--[@b19]^ However, the degree of chronotropic incompetence did not improve following PEA despite a clear reduction of resting pulmonary vascular hemodynamics. It is possible that the remaining chronotropic impairment in post‐PEA patients reflects the persisting RV pressure overload and functional impairment during exercise. Another putative mechanism may be that chronic right atrial stretch due to longstanding RV pressure overload prior to PEA‐induced electrical and structural remodeling of the right atrium and sinus node,^[@b20]--[@b21]^ which might not be fully reversible after PEA.

Response of the Right Ventricle to Increased Afterload During Exercise
----------------------------------------------------------------------

In this study, we also evaluated the impact of an abnormal exercise‐induced increase in RV afterload on RV performance itself. This is important because RV function is the primary determinant of exercise capacity and outcome in PH, irrespective of changes in PVR.^[@b8]^ When evaluated at rest, CO and RV performance were indistinguishable between post‐PEA patients and controls, indicating that RV contractility was sufficiently preserved to maintain optimal coupling between the RV and the pulmonary circulation at rest. Imaging during exercise enables quantification of RV contractile reserve as the change in RVEF or SV from rest to maximal exercise.^[@b22]^

We observed that the post‐PEA patients had a similar increase in SV from rest to peak exercise compared to healthy subjects, suggesting that RV contractile reserve was preserved. However, the mechanisms by which the RV generated the increased SV during exercise were significantly different between post‐PEA patients and healthy subjects. In healthy subjects, SV augmentation is mainly achieved by a decrease in ESV, reflecting contractile reserve, whereas EDV remains relatively unchanged or decreases slightly at near‐maximal exercise due to reduced filling times.^[@b9]^ In contrast, the exercise‐induced increase in SV in the post‐PEA patients was achieved by concomitant increases in RV EDV and ESV. Thus, RVEF did not increase during exercise (Figures [2](#fig02){ref-type="fig"} and [3](#fig03){ref-type="fig"}). This suggests that, although global RV performance is preserved, the RV becomes more dependent upon Frank--Starling recoil to meet its output requirements in post‐PEA patients. A recent study in patients with long‐term pulmonary arterial hypertension and a clinically stable profile demonstrated that preserved CO may mask RV failure progression, and that changes in RV volumes may be sensitive parameters to predict ultimate deterioration, even at the time of clinical stability.^[@b23]^ Therefore, evaluation of RV volumes and RVEF during exercise may be clinically important to detect early RV failure development.

Pulmonary Arterial Compliance Decreases During Exercise
-------------------------------------------------------

Resistance does not adequately describe afterload when considering the pulsatile nature of the circulation. C~PA~ represents the ability of the pulmonary circulation to stretch in response to an applied pressure, and its inverse relationship with PVR means that small increases in PVR are associated with large decreases in C~PA~, thereby making it an important marker of early pulmonary vascular disease.^[@b24]--[@b25]^ Previous studies have demonstrated that the product of C~PA~ and PVR remains constant over time and suggested that a pathologic hemodynamic response to exercise is characterized by an increase in PVR together with a decrease in C~PA~.^[@b7],[@b24]^ However, Tedford et al showed that the coupling between C~PA~ and PVR can change during exercise in patients with left‐sided heart disease because of an increase in PCWP.^[@b26]^ More recently, MacKenzie Ross et al showed that it is not only an increase in PCWP that can change the product of PVR and C~PA~, but also that proximal CTEPH and PEA surgery are able to alter this relationship.^[@b27]^

In this study, we extend these findings by demonstrating that in healthy subjects, both tPVR and C~PA~ decrease during exercise. Therefore, the product of tPVR and C~PA~ does not remain fixed from rest to exercise in healthy subjects, but C~PA~ becomes lower for any given value of tPVR (Figures [4](#fig04){ref-type="fig"} and [5](#fig05){ref-type="fig"}). The reduction of C~PA~ during exercise can be explained by passive distention of the pulmonary vascular vessels with increasing CO such that the vessels become stiffer (less compliant) as their diameter increases.^[@b28]^ Exercise‐associated sympathetic nervous system stimulation may be another mechanism to explain the decrease in C~PA~ during exercise in healthy subjects.^[@b29]--[@b30]^ Indeed, it has been shown in normal dogs that sympathetic nervous system activation may increase characteristic impedance without significantly changing PVR.^[@b30]^

Intriguingly, the reduction in RC time during exercise was most profound in the control subjects, indicating that the relative increase in pulsatile load during exercise is greater in healthy individuals than in CTEPH and post‐PEA patients. However, the greater reduction in RC time is a simple consequence of the fact that the compliance and resistance of the pulmonary vasculature were far better in healthy subjects at baseline. As explained above, at maximal exercise there is a convergence whereby the pulmonary circulation became "stiff". In healthy subjects this occurred at very high COs when the vascular resistance was low, whereas in the CTEPH patients this point was reached with only very modest increase in CO and no reduction in PVR. Another mechanism that may have contributed to the proportionately greater reduction in C~PA~ in healthy controls may be the higher exercise‐induced increase in heart rate. It has been shown for both the systemic and the pulmonary circulation that an increase in heart rate is associated with a reduction in arterial compliance.^[@b31]--[@b32]^ Thus, the change in C~PA~ during exercise per se cannot be used to distinguish between a normal and abnormal pulmonary vascular reserve. Nevertheless, whereas controls demonstrated the greatest reductions in C~PA~ during exercise, peak exercise values still remained higher than the resting values in CTEPH and post‐PEA patients. Moreover, despite the relatively greater contribution of pulsatile load, the total RV load remained much lower in the healthy subjects as reflected by the lower peak exercise mPAP and tPVR.

Effects of Sildenafil on Exercise Hemodynamics in Post‐PEA Patients
-------------------------------------------------------------------

Our study extends current understanding of the pathophysiology of exercise intolerance in post‐PEA patients with potential therapeutic implications. Skoro‐Sajer et al demonstrated that up to 77.7% of CTEPH patients have some degree of pulmonary vascular reactivity during nitric oxide administration prior to PEA, indicating distal vasoconstriction, and that a decrease in mPAP \>10% predicts immediate postoperative PVR decrease and better long‐term outcome after PEA.^[@b33]^ Our current results indicate that even after successful PEA some residual pulmonary vasoconstriction remains present, which can be partially reversed after administration of a pulmonary vasodilator. Importantly, the beneficial effects of sildenafil were measurable during exercise, but not at rest. It is yet to be determined whether the short‐term improvements in exercise hemodynamics and RV function following sildenafil administration translate to improved clinical outcomes with long‐term pulmonary vasodilators. Our study provides a rationale for investigating the efficacy of post‐PEA pulmonary vasodilator therapy and suggests that exercise metrics should be included in the outcome measures.

Limitations
-----------

This is the largest series to include invasive pulmonary artery measures in CTEPH patients and healthy controls. Recruiting healthy controls for such a study is challenging and is seldom attempted. In this context, we felt that the very small but potentially serious potential for adverse events in performing PCWP measurements during exercise was unacceptable, so PCWP was only measured at rest in the CTEPH and post‐PEA patients and no PCWP measurements were obtained in controls. Therefore, we could not assess the degree to which PCWP influenced the changes in C~PA~ and PVR observed during exercise. Although PCWP can increase to as high as 30 mm Hg in exercising athletes,^[@b34]^ increases in PCWP only become significant at very high COs,^[@b35]^ whereas we observed a reduction in C~PA~ even during low‐intensity exercise.

Secondly, given the constraints of recruiting healthy subjects for an invasive study protocol and the low community prevalence of CTEPH, we did not attempt to match the control, CTEPH, and post‐PEA cohorts for age. Nevertheless, the RV pressure--volume response to exercise remained significantly different between control subjects and post‐PEA patients when only the oldest controls, matched for age, were considered in a subanalysis ([Table 3](#tbl03){ref-type="table"}). Also, the small sample size may have increased the probability of type II statistical errors due to lack of power, whereas the use of multiple comparisons increased the chances of type I errors. We have addressed the latter concern by increasing the significance level required for rejecting the null hypothesis to *P*\<0.01. The established accuracy of exercise CMR measures enabled us to evaluate meaningful hemodynamic differences within this modest‐sized cohort with high levels of statistical significance. Lastly, the use of a fluid‐filled catheter to calculate pulse pressure can be problematic due to catheter ringing, particularly in healthy subjects where small changes in pulse pressure can lead to significant differences in compliance.^[@b36]^ High‐fidelity micromanometer‐tipped catheters would have provided more precise pressure measures but are unable to be used in the CMR environment.

Conclusions
===========

Despite normalized hemodynamics at rest, post‐PEA patients have significant exercise intolerance, which is explained by abnormal pulmonary vascular reserve and chronotropic incompetence. The mPAP/CO slope and C~PA~ are sensitive measures of resistive and pulsatile pulmonary vascular function, which correlate strongly with exercise capacity. Sildenafil partially attenuates abnormalities in post‐PEA hemodynamics, providing rationale for studies investigating the efficacy of chronic pulmonary vasodilator therapy in this group.
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